Kazia Therapeutics Ltd 6-K, filed Nov 16, 2022
Kazia Therapeutics Ltd (KZIA)
About this 6-K
Kazia Therapeutics Ltd filed this 6-K on November 16, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November, 2022
Commission File Number 000-29962
Kazia Therapeutics Limited
(Translation of registrant’s name into English)
Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☑ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On November 16, 2022, Kazia Therapeutics Limited (the “Company”) issued an ASX release titled “Annual General Meeting Results” in connection with its Annual General Meeting that was held on November 16, 2022 at 10:00 a.m. (Sydney time).
The Company hereby incorporates by reference the information contained herein into the Company’s registration statement on Form F-3 (File No. 333-259224).
EXHIBIT LIST
| Exhibit |
Description | |
| 99.1 | ASX Release of Kazia Therapeutics Limited dated November 16, 2022 (Annual General Meeting Results) | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Kazia Therapeutics Limited (Registrant) |
| /s/ Karen Krumeich |
| Karen Krumeich |
| Chief Financial Officer |
| Date: November 16, 2022 |
Exhibit 99.1
ASX RELEASE
16 November 2022
AGM MATERIALS
Sydney, 16 November 2022 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to provide the results of the Company’s AGM, held earlier today.
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia.
Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed phase II study in glioblastoma reported promising signals of efficacy in 2021, and a pivotal study for registration, GBM AGILE, is ongoing, with final data expected in 2H CY2023. Other clinical trials are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these having reported encouraging interim data.
Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020, and for atypical teratoid / rhabdoid tumours (AT/RT) in June 2022 and July 2022, respectively.
Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study commenced recruitment in November 2021.
For more information, please visit www.kaziatherapeutics.com or follow us on Twitter @KaziaTx.
This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director.
Kazia Therapeutics Limited
Annual General Meeting
Wednesday, 16 November 2022
Results of Meeting
The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.
| Resolution details |
Instructions given to validly appointed proxies (as at proxy close) |
Number of votes cast on the poll (where applicable) |
Resolution Result | |||||||||||||||
| Resolution |
Resolution Type |
For | Against | Proxy’s Discretion |
Abstain | For | Against | Abstain* | Carried / Not Carried | |||||||||
| 1 Adoption of Remuneration Report | Ordinary | 18,737,349 61.03% |
11,787,139 38.39% |
177,839 0.58% |
27,022,451 | 19,252,815 62.03% |
11,787,139 37.97% |
27,022,451 | Carried | |||||||||
| 2 Re-Election of Steven Coffey | Ordinary | 52,294,495 89.24% |
6,126,952 10.46% |
178,439 0.30% |
2,099,020 | 52,804,989 89.60% |
6,126,952 10.40% |
2,104,592 | Carried | |||||||||
| 3 Approval of grant of Options to Dr James Garner | Ordinary | Resolution withdrawn | Resolution withdrawn | Not Applicable | ||||||||||||||
| 4 Ratification of prior issue of ATM Shares | Ordinary | 50,147,662 83.12% |
10,002,735 16.58% |
178,439 0.30% |
370,070 | 50,663,728 83.51% |
10,002,735 16.49% |
370,070 | Carried | |||||||||
| 5 Approval of Additional Placement Capacity under Listing Rule 7.1A | Special | 50,006,395 83.41% |
9,613,179 16.04% |
327,938 0.55% |
751,394 | 50,671,960 84.05% |
9,613,179 15.95% |
751,394 | Carried | |||||||||
| 6 Adoption of New Constitution | Special | 52,170,337 87.47% |
7,279,241 12.20% |
198,439 0.33% |
1,050,889 | 52,700,831 87.86% |
7,279,241 12.14% |
1,056,461 | Carried | |||||||||
| 7 Approval of Proportional Takeover Provisions | Special | 54,531,437 90.38% |
5,622,998 9.32% |
178,439 0.30% |
366,032 | 55,041,931 90.73% |
5,622,998 9.27% |
371,604 | Carried | |||||||||
| * | Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. |
In relation to resolution 1 Adoption of Remuneration Report, as more than 25% of the votes were cast against this resolution, this constitutes a first strike for the purposes of the Corporations Act 2001 (Cth).
Resolution(s) proposed but not put to the meeting
| Resolution |
Reason(s) for not putting the resolution to the meeting | |
| 3 Approval of grant of Options to Dr James Garner | Resolution withdrawn prior to AGM |